Perceptive Advisors LLC Buys 125,000 Shares of Inhibrx Biosciences, Inc. $INBX

Perceptive Advisors LLC grew its stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 9.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,452,707 shares of the company’s stock after acquiring an additional 125,000 shares during the period. Inhibrx Biosciences accounts for approximately 2.0% of Perceptive Advisors LLC’s holdings, making the stock its 11th largest position. Perceptive Advisors LLC owned approximately 9.99% of Inhibrx Biosciences worth $114,764,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Strs Ohio bought a new position in Inhibrx Biosciences during the first quarter worth about $27,000. Persistent Asset Partners Ltd bought a new position in Inhibrx Biosciences during the fourth quarter worth about $27,000. Public Employees Retirement System of Ohio bought a new position in Inhibrx Biosciences during the third quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Inhibrx Biosciences by 26.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock worth $56,000 after purchasing an additional 147 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Inhibrx Biosciences by 71.9% during the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after purchasing an additional 789 shares during the period. Institutional investors own 82.46% of the company’s stock.

Inhibrx Biosciences Trading Up 1.2%

Shares of INBX stock opened at $94.20 on Thursday. The firm has a 50 day moving average price of $102.15 and a two-hundred day moving average price of $85.25. The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. The company has a market capitalization of $1.38 billion, a PE ratio of -11.23 and a beta of 3.31. Inhibrx Biosciences, Inc. has a 12-month low of $13.97 and a 12-month high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.47). As a group, analysts predict that Inhibrx Biosciences, Inc. will post -10.15 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Tuesday. Zacks Research upgraded Inhibrx Biosciences to a “hold” rating in a report on Thursday, April 9th. Stifel Nicolaus assumed coverage on Inhibrx Biosciences in a report on Wednesday, April 8th. They set a “buy” rating and a $150.00 price target for the company. Wall Street Zen upgraded Inhibrx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $150.00.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.